NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
Clinical Trials
18 trialsNCT04744831 2026-01-14
DESTINY-CRC02
Daiichi Sankyo
Phase 2 Completed
NCT04644237 2025-11-21
DESTINY-LUNG02
Daiichi Sankyo
Phase 2 Completed
NCT06386263 2025-10-15
HER-TEMPO
AstraZeneca
Completed
NCT04539938 2025-09-30
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT06504719 2025-09-15
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Hellenic Cooperative Oncology Group
Completed
NCT04420598 2025-06-24
DEBBRAH
MedSIR
Phase 2 Completed
NCT04132960 2025-06-12
DAISY
UNICANCER
Phase 2 Completed
NCT04014075 2025-04-03
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Daiichi Sankyo
Phase 2 Completed
NCT03523572 2025-01-27
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
Phase 1 Completed
NCT04989816 2024-11-21
DG-06
AstraZeneca
Phase 2 Completed
NCT05458401 2024-03-15
EUROPA T-DXd
Daiichi Sankyo
Completed
NCT02564900 2024-01-22
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03383692 2023-12-11
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT04752059 2023-05-12
TUXEDO-1
Medical University of Vienna
Phase 2 Completed
NCT03368196 2022-11-03
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Daiichi Sankyo
Phase 1 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT03384940 2021-10-18
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
Daiichi Sankyo
Phase 2 Completed